{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:48:15Z","timestamp":1762854495148,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:00:00Z","timestamp":1717286400000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.gofs.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T11:53:27Z","timestamp":1681127607000},"page":"352-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toxicit\u00e9 f\u0153tale et n\u00e9onatale des inhibiteurs de l\u2019enzyme de conversion et des sartans\u00a0: quelle surveillance pour les enfants expos\u00e9s in utero\u00a0?"],"prefix":"10.1016","volume":"51","author":[{"given":"B\u00e9n\u00e9dicte","family":"Coulm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Latour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Vauzelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"\u00c9l\u00e9fant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Ulinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gofs.2023.04.003_bib0125","unstructured":"Assurance maladie, AMELI. Open Medic\u00a0: bases compl\u00e9mentaires sur les d\u00e9penses de m\u00e9dicaments en 2021. Disponible en ligne\u00a0: https:\/\/assurance-maladie.ameli.fr\/etudes-et-donnees\/open-medic-depenses-beneficiaires-medicaments-2021.(consult\u00e9 le 30\u00a0mars 2023)."},{"key":"10.1016\/j.gofs.2023.04.003_bib0130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/11589170-000000000-00000","article-title":"Drug prescribing before and during pregnancy in south west France: a retrolective study","volume":"34","author":"Crespin","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.gofs.2023.04.003_bib0135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/pds.4265","article-title":"Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample","volume":"26","author":"Demailly","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.gofs.2023.04.003_bib0140","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40264-021-01117-4","article-title":"Dispensing of potentially harmful prescription drugs in 1.8\u00a0million pregnant women in france: a nationwide study based on two risk classification systems","volume":"44","author":"Bloti\u00e8re","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.gofs.2023.04.003_bib0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.reprotox.2011.02.008","article-title":"Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers","volume":"31","author":"Diav-Citrin","year":"2011","journal-title":"Reprod Toxicol Elmsford N"},{"key":"10.1016\/j.gofs.2023.04.003_bib0150","doi-asserted-by":"crossref","first-page":"d5931","DOI":"10.1136\/bmj.d5931","article-title":"Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study","volume":"343","author":"Li","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.gofs.2023.04.003_bib0155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/AOG.0000000000001775","article-title":"Angiotensin-converting enzyme inhibitors and the risk of congenital malformations","volume":"129","author":"Bateman","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2023.04.003_bib0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.preghy.2018.04.022","article-title":"Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study","volume":"13","author":"Hoeltzenbein","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.gofs.2023.04.003_bib0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/01443615.2011.579197","article-title":"Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers","volume":"31","author":"Walfisch","year":"2011","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.gofs.2023.04.003_bib0170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/bdra.23027","article-title":"Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence","volume":"94","author":"Polifka","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.gofs.2023.04.003_bib0175","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors","volume":"354","author":"Cooper","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gofs.2023.04.003_bib0180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/tera.1420500606","article-title":"Teratogen update: angiotensin-converting enzyme inhibitors","volume":"50","author":"Barr","year":"1994","journal-title":"Teratology"},{"key":"10.1016\/j.gofs.2023.04.003_bib0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/HJH.0000000000002233","article-title":"Fetotoxic risk of AT1\u00a0blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study","volume":"38","author":"Weber-Schoendorfer","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.gofs.2023.04.003_bib0190","doi-asserted-by":"crossref","first-page":"SP245","DOI":"10.2131\/jts.34.SP245","article-title":"Children's toxicology from bench to bed-drug-induced renal injury (1): the toxic effects of ARB\/ACEI on fetal kidney development","volume":"34","author":"Sekine","year":"2009","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.gofs.2023.04.003_bib0195","article-title":"Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists","volume":"19","author":"Lallemant","year":"2018","journal-title":"J Renin-Angiotensin-Aldosterone Syst JRAAS"},{"key":"10.1016\/j.gofs.2023.04.003_bib0200","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/ki.2009.423","article-title":"Renin-angiotensin system in kidney development: renal tubular dysgenesis","volume":"77","author":"Gubler","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.gofs.2023.04.003_bib0205","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pd.3960","article-title":"Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers","volume":"32","author":"Spaggiari","year":"2012","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.gofs.2023.04.003_bib0210","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00467-008-1091-8","article-title":"Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker","volume":"24","author":"Miura","year":"2009","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"10.1016\/j.gofs.2023.04.003_bib0215","doi-asserted-by":"crossref","first-page":"5412138","DOI":"10.1155\/2018\/5412138","article-title":"Long-term consequences of fetal angiotensin II receptor antagonist exposure","volume":"2018","author":"Wegleiter","year":"2018","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.gofs.2023.04.003_bib0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/bdra.20047","article-title":"Fetal toxicity of valsartan and possible reversible adverse side effects","volume":"70","author":"Berkane","year":"2004","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.gofs.2023.04.003_bib0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1345\/aph.1E250","article-title":"Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth","volume":"39","author":"Bos-Thompson","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gofs.2023.04.003_bib0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.reprotox.2009.02.004","article-title":"receptor blockers in pregnancy: a report of five cases","volume":"28","author":"Gersak","year":"2009","journal-title":"Reprod Toxicol Elmsford N"},{"key":"10.1016\/j.gofs.2023.04.003_bib0235","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.reprotox.2010.01.010","article-title":"Reversible fetal renal failure after maternal treatment with Candesartan: a case report","volume":"29","author":"Munk","year":"2010","journal-title":"Reprod Toxicol Elmsford N"},{"key":"10.1016\/j.gofs.2023.04.003_bib0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0030-1269895","article-title":"Angiotensin II receptor blocker induced fetopathy: 7\u00a0cases","volume":"223","author":"H\u00fcnseler","year":"2011","journal-title":"Klin Padiatr"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718923001009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718923001009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:44:10Z","timestamp":1762854250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718923001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2468718923001009"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2023.04.003","relation":{},"ISSN":["2468-7189"],"issn-type":[{"type":"print","value":"2468-7189"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9 f\u0153tale et n\u00e9onatale des inhibiteurs de l\u2019enzyme de conversion et des sartans\u00a0: quelle surveillance pour les enfants expos\u00e9s in utero\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}